Biological therapies for myasthenia gravis

References

• Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5):475–490.
   PubMed Web of Science ®Google Scholar
• Conti-Fine BM, Milani M, Kaminski HJ, Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–2854.
   PubMed Web of Science ®Google Scholar
• Mori S, Kubo S, Akiyoshi T, et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol. 2012;180(2):798–810.
   PubMed Web of Science ®Google Scholar
• Utsugisawa K, Nagane Y, Akaishi T, et al. Early fast-acting treatment strategy against generalized myasthenia gravis. Muscle Nerve. 2017;55(6):794–801.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Suzuki S, Kuwabara S, et al. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2023. In press. DOI: 10.1136/jnnp-2022-330519.
   PubMedGoogle Scholar
• Suzuki S, Masuda M, Uzawa A, et al. Japan MG Registry: chronological surveys over 10 years. Clin Exp Neuroimmunol. 2023;14(1):5–12.
   Google Scholar
• Masuda M, Utsugisawa K, Suzuki S, et al. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve. 2012;46(2):166–173.
   PubMed Web of Science ®Google Scholar
• Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11:1756285617749134.
   Web of Science ®Google Scholar
• Murai H, Utsugisawa K, Motomura M, et al. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome. Clin Exp Neuroimmunol. 2023;14(1):19–27.
   Google Scholar
• Engel AG, Arahata K. The membrane attack complex of complement at the endplate in myasthenia gravis. Ann N Y Acad Sci. 1987;505(1 Myasthenia Gr):326–332.
   PubMedGoogle Scholar
• Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc. 1977;52(5):267–280.
   PubMed Web of Science ®Google Scholar
• Sahashi K, Engel AG, Lambert EH, et al. Ultrastructural Localization of the Terminal and Lytic Ninth Complement Component (C9) at the Motor End-plate in Myasthenia Gravis. J Neuropathol Exp Neurol. 1980;39(2):160–172.
   PubMed Web of Science ®Google Scholar
• Ozawa Y, Uzawa A, Yasuda M, et al. Changes in serum complements and their regulators in generalized myasthenia gravis. Eur J Neurol. 2021;28(1):314–322.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Gong B, Lin F, et al. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol. 2007;179(12):8562–8567.
   PubMed Web of Science ®Google Scholar
• Howard JF, Utsugisawa K, Benatar M, et al., Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976–986.
   PubMed Web of Science ®Google Scholar
• McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–737.
   PubMed Web of Science ®Google Scholar
• Murai H, Suzuki S, Hasebe M, et al. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Ther Adv Neurol Disord. 2021;14:17562864211001995.
   Web of Science ®Google Scholar
• Vu T, Meisel A, Mantegazza R, et al., Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):EVIDoa2100066.
   Google Scholar
• Howard JF, Vissing J, Gilhus NE, et al., Zilucoplan: an Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis. Expert Opin Investig Drugs. 2021;30(5):483–493.
   PubMed Web of Science ®Google Scholar
• Howard JF, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77(5):582–592.
   PubMed Web of Science ®Google Scholar
• Pyzik M, Sand KMK, Hubbard JJ, et al. The neonatal Fc receptor (FcRn): a misnomer? Front Immunol. 2019;10:1540.
   PubMed Web of Science ®Google Scholar
• Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–536.
   PubMed Web of Science ®Google Scholar
• Bril V, Benatar M, Andersen H, et al., Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: a Phase 2 Randomized Control Trial. Neurology. 2021;96(6):e853–e865.
   PubMed Web of Science ®Google Scholar
• Guptill J, Antozzi C, Bril V, et al. Vivacity-MG: a phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis (2157). Neurology [Internet]. 2021;96(15 Supplement). available from: https://n.neurology.org/content/96/15_Supplement/2157
   Web of Science ®Google Scholar
• Yan C, Duan R-S, Yang H, et al., Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol Ther. 2022;11(2):815–834.
   PubMed Web of Science ®Google Scholar
• Tandan R, Hehir MK 2nd, Waheed W, et al. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017;56(2):185–196.
   PubMed Web of Science ®Google Scholar
• Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology. 2022;98(4):e376–e389.
   Web of Science ®Google Scholar
• Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 2022;79(11):1105–1112.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Akamine H, Kojima Y, et al. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis. J Neuroimmunol. 2021;358:577634.
   PubMed Web of Science ®Google Scholar
• Aricha R, Mizrachi K, Fuchs S, et al. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun. 2011;36(2):135–141.
   PubMed Web of Science ®Google Scholar
• Jonsson DI, Pirskanen R, Piehl F. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscul Disord. 2017;27(6):565–568.
   PubMed Web of Science ®Google Scholar
• Esfandiari E, Chen M, Smithson G, et al. A phase I, randomized, double-blind, placebo-controlled, single-dose and multiple-rising-dose study of the BTK inhibitor TAK-020 in healthy subjects. Clin Transl Sci. 2021;14(3):820–828.
   PubMed Web of Science ®Google Scholar
• Kohler S, Märschenz S, Grittner U, et al. Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial. BMJ Open. 2019;9(1):e024523.
   PubMed Web of Science ®Google Scholar
• Gomez AM, Vrolix K, Martínez-Martínez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol. 2011;186(4):2503–2513.
   PubMed Web of Science ®Google Scholar
• Beecher G, Putko BN, Wagner AN, et al. Therapies directed against B-Cells and downstream effectors in generalized autoimmune myasthenia gravis: current status. Drugs. 2019;79(4):353–364.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Kuwabara S, Suzuki S, et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366–374.
   PubMed Web of Science ®Google Scholar
• Kang SY, Kang CH, Lee KH. B-cell-activating factor is elevated in serum of patients with myasthenia gravis. Muscle Nerve. 2016;54(6):1030–1033.
   PubMed Web of Science ®Google Scholar
• Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive Belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425–e1434.
   PubMed Web of Science ®Google Scholar
• Ristov J, Espie P, Ulrich P, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018;18(12):2895–2904.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113–124.
   PubMed Web of Science ®Google Scholar